Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Zhenfeng, Lee, Jae Cheol, Lin, Luping, Olivas, Victor, Au, Valerie, LaFramboise, Thomas, Abdel-Rahman, Mohamed, Wang, Xiaoqi +22 more·2012·Nature Genetics

DOI 10.1038/ng.2330

Cited by (1,000)

Items 901–1,000 of 1,000

Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells
Pol Giménez‐Xavier, Eva Pros, Ana Aza, Sebastián Morán, Raúl Tonda, Anna Esteve‐Codina, Marc Dabad, Montse Sánchez‐Céspedes · 2018 · Oncotarget
Targeting TAM to Tame Pancreatic Cancer
Mitchell S. von Itzstein, Michael Burke, Rolf A. Brekken, Todd Anthony Aguilera, Herbert J. Zeh, Muhammad Shaalan Beg · 2020 · Targeted Oncology
Efficacy of newly discovered DNA aptamers targeting AXL in a lung cancer cell with acquired resistance to Erlotinib
Ji An Hwang, Jae Young Hur, Youndong Kim, Jong Hun Im, Seong Hui Jin, Sung Ho Ryu, Chang‐Min Choi · 2021 · Translational Cancer Research
Dual targeting of TAM receptors Tyro3, Axl, and MerTK
Kai‐Hung Wang, Dah‐Ching Ding · 2021 · Tzu Chi Medical Journal
Tissue Microarray Analyses Suggest Axl as a Predictive Biomarker in HPV-Negative Head and Neck Cancer
Chia‐Jung Busch, Christian Hagel, Benjamin Becker, Agnes Oetting, Nikolaus Möckelmann, Conrad Droste, Christina Möller‐Koop, Melanie Witt, Markus Blaurock, Sonja Loges et al. · 2022 · Cancers
Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models
Salvador Guardiola, Macarena Sánchez‐Navarro, Rafael Rosell, Ernest Giralt, Jordi Codony‐Servat · 2022 · Medical Oncology
High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
Youyou Xie, Dongqing Lv, Wei Wang, Minhua Ye, Xiaofeng Chen, Haihua Yang · 2017 · Oncotarget
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer
Marjan Mojtabavi Naeini, Manoochehr Tavassoli, Kamran Ghaedi · 2018 · Gene
Machine learning identifies a core gene set predictive of acquired resistance to EGFR tyrosine kinase inhibitor
Young Rae Kim, Sung Young Kim · 2018 · Journal of Cancer Research and Clinical Oncology
Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non–small cell lung cancer
Juliana Rodrigues Machado Rúgolo, Alexandre Todorovic Fabro, Daniel Ascheri, Cecília Farhat, Alexandre Muxfeldt Ab’Saber, Vanessa Karen de Sá, María Aparecida Nagai, Teresa Yae Takagaki, Ricardo Mingarini Terra, Edwin Roger Parra et al. · 2018 · Human Pathology
Personalized Prediction of Acquired Resistance to EGFR-Targeted Inhibitors Using a Pathway-Based Machine Learning Approach
Young Rae Kim, Yong Kim, Suh Lee, Hye Jin Yang, Sung Young Kim · 2019 · Cancers
Navigating TAM receptor dynamics in tumour immunotherapy
Jihao Yang, Guanmin Chen, Rui Ying Wang, Chengcheng Song, Huaqiang Yi · 2025 · Cancer Immunology Immunotherapy
Recent advances in TAM mechanisms in lung diseases
Jia-Qi Ban, Jiayi Qian, Chi Zhang, Jun Li · 2025 · Journal of Translational Medicine
The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor–Resistant NSCLC and Drug-Tolerant Persister Cells
Yan Yang, Monique B. Nilsson, Xiaoxing Yu, Alissa Poteete, Hong Jiang, Qian Huang, Junqin He, Simon Heeke, John Victor Heymach · 2025 · Clinical Cancer Research
Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors
Zijian Liu, Rui Wang, Ruiming Guo, Jinxing Hu, Ruijuan Li, Yanfang Zhao, Ping Gong · 2014 · Bioorganic & Medicinal Chemistry
Phenotypic plasticity promotes lymph nodes metastasis and drug resistance in lung squamous cell carcinomas
Feng Wang, Lei Zhu · 2023 · Heliyon
Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor
Xi Wang, Dainan Zhang, Xiudong Guan, Shunchang Ma, Wenjianlong Zhou, Jiayi Peng, Linhao Yuan, Yangyang Wang, Shucheng Jin, Qin Xu et al. · 2023 · Translational Lung Cancer Research
A procedure for producing an anti-AXL nanobody in E. coli
Zhongyun Lan, Lingyun Li, Yili Sun, Xiangjing Meng, Zhenzhong Shi, Mengyang Du, Hui Wang, Zengchao Sun, Qianqian Cui, Lu Wang et al. · 2023 · Protein Expression and Purification
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
Shen Zhao, Yuxiang Ma, Lianke Liu, Jian Fang, Haiqing Ma, Guosheng Feng, Bo Xie, Shan Zeng, Jianhua Chang, Jun Ren et al. · 2024 · Lung Cancer
Efficacy and Safety of Amivantamab in Advanced or Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review
Ionas Papassotiriou, Antonios Kapogiannatos, C. Makatsoris, Sabrina Bakogeorgou, Ioanna Mantogiannakou, Emmanouela Roussou, Georgios Souras, Dimitris Liakas, Theodoros Ν. Sergentanis, Maria Gavriatopoulou et al. · 2024 · Journal of Clinical Medicine
PFKP silencing suppresses tumor growth via the AXL-MET axis
Huijie Zhao, Yuze Sun, Huijing Feng, Jing Cai, Yue Liu, Yu Li, Sijie Chen, Zhiqing Zhou, Yuhui Du, Xiaofei Zeng et al. · 2024 · International Journal of Biological Sciences
The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistance
Ahmad Dawalibi, Mohamad Adel Bakir, Khalid Said Mohammad · 2025 · Cancer Drug Resistance
miRNAs: Mediators of Erbb Family Targeted Therapy Resistance
Bárbara Adem, Nuno Bastos, Francisca Dias, Ana Luísa Teixeira, Rui Medeiros · 2016 · Pharmacogenomics
IQGAP1 binds the Axl receptor kinase and inhibits its signaling
Laëtitia Gorisse, Zhigang Li, Andrew C. Hedman, David B. Sacks · 2018 · Biochemical Journal
An In Vivo Inflammatory Loop Potentiates KRAS Blockade
Kristina A. M. Arendt, Giannoula Ntaliarda, Vasileios Armenis, Danai Kati, Christin Henning, Georgia A. Giotopoulou, Mario A. A. Pepe, Laura Valentina Klotz, Anne‐Sophie Lamort, Rudolf Alexander Hatz et al. · 2022 · Biomedicines
Engineering Multivalent and Multispecific Protein Therapeutics
Cassie J. Liu, Jennifer R. Cochran · 2013 · Springer eBooks
Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
Zhigang Wei, Xin Ye, Xia Yang, Aimin Zheng, Guanghui Huang, Wenhong Li, Jiao Wang, Xiaoying Han, Min Meng, Yang Ni · 2017 · Oncotarget
Post-column infused internal standard assisted lipidomics profiling strategy and its application on phosphatidylcholine research
Hsiao‐Wei Liao, Ching‐Hua Kuo, Hsi‐Chun Chao, Guan‐Yuan Chen · 2019 · Journal of Pharmaceutical and Biomedical Analysis
Quantitative Structure-Activity relationship, Molecular Docking and ADMET Screening of Tetrahydroquinoline Derivatives as Anti-Small Cell Lung Cancer Agents
Ehimen Annastasia Erazua, Abel Kolawole Oyebamiji, Sunday Adewale Akintelu, Pelumi Daniel Adewole, Adedayo Adelakun, B. B. Adeleke · 2023 · Eclética Química
Chemoresistance of Lung Cancer Cells: 2D and 3D In Vitro Models for Anticancer Drug Screening
Vivek Kaushik, Juan Sebastián Yakisich, Yogesh Kulkarni, Neelam Azad, Anand Krishnan V. Iyer · 2018 · InTech eBooks
Very Late Antigen-5 Facilitates Stromal Progenitor Cell Differentiation Into Myofibroblast
Namita Sen, Mark Weingarten, Yakov Peter · 2014 · Stem Cells Translational Medicine
From Bench to Bedside: A Team’s Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
Bridget E. Crossman, Regan L. Harmon, Kourtney L. Kostecki, Nellie K. McDaniel, Mari Iida, Luke W. Corday, Christine E. Glitchev, Madisen T. Crow, Madelyn A. Harris, Candie Y Lin et al. · 2024 · Journal of Clinical Medicine
Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress
Akash Sabarwal, Marc Machaalani, Laxminarayan Rawat, Johannes Wedel, Saba Tabasum, Yuzuru Sasamoto, Florian Buerger, Josie Ascione, Marc Eid, Karl Semaan et al. · 2025 · Cancer Letters
Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies
Ting Wang, Wenjie Jiang, Liyan Yang, Jinqi Li, Yiqi Sun, Jianyou Shi · 2025 · Bioorganic Chemistry
Tumor Cell Plasticity in Cancer: Signaling Pathways and Pharmaceutical Interventions
Shangwei Sun, Yunwei Sun, Ling Lan, Siyuan Luan, Jin Rong Zhou, Jiehui Deng, Yong Yuan, Zhong Wu · 2025 · MedComm
AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?
Marinus R. Heideman, Nancy E. Hynes · 2013 · Breast Cancer Research
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth
Kathryn A. Mills, Samuel Tanner Roach, Jeanne M. Quinn, Lei Guo, Hollie Beck-Noia, Elena E. Lomonosova, Anna R. Ilivicky, Courtney M. Starks, Julie A. Lawrence, Andrea R. Hagemann et al. · 2018 · Gynecologic Oncology
p70S6K Promotes Acquired Resistance of Erlotinib Through Induction of Epithelial-Mesenchymal Transition in Non-Small Cell Lung Carcinoma
Min Li, Hongling Chen, Tong Sun, Zhuo Ma, Xi Chen, Dandan Wu, Wenbin Huang, Xuerong Wang · 2020 · OncoTargets and Therapy
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
Antonia Beitzen‐Heineke, Nikolaus Berenbrok, Jonas S. Waizenegger, Sarina Päsler, Victoria Gensch, Florian Udonta, Maria Elena Vargas Delgado, Janik Engelmann, Friederike Hoffmann, Philippe Schafhausen et al. · 2021 · HemaSphere
AXL cooperates with EGFR to mediate neutrophil elastase-induced migration of prostate cancer cells
Zhiguang Xiao, Stephen R. Hammes · 2021 · iScience
Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
Emna Mahfoudhi, Charles Ricordel, Gwendoline Lécuyer, Cécile Mouric, H. Léna, Rémy Pedeux · 2022 · Frontiers in Oncology
Induction of Multiple Alternative Mitogenic Signaling Pathways Accompanies the Emergence of Drug-Tolerant Cancer Cells
Frank Celeste, Scott Powers · 2024 · Cancers
Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?
Shayan Khalafi, Albert Craig Lockhart, Alan S. Livingstone, Wael M. El-Rifai · 2020 · Cancers
AXL receptor as an emerging molecular target in colorectal cancer
Lucía De Rosa, Rossella Di Stasi, Virginia Fusco, Luca Domenico D’Andrea · 2024 · Drug Discovery Today
Novel anti-human Axl monoclonal antibodies for improved patient biomarker studies
Lavina Ahmed, Sergej M. Kiprijanov, Hawa Nalwoga, Katarzyna Wnuk-Lipińska, Hallvard Haugen, James B. Lorens, Lars A. Akslen, David Micklem · 2016 · Verein zur Förderung des biologisch technologischen Fortschritts in der Medizin e.V.
The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein–protein interaction in glioblastoma
Virginie Neirinckx, Ann‐Christin Hau, Anne M. Schuster, Sabrina Fritah, Katja Tiemann, Eliane Klein, Petr V. Nazarov, André Matagne, Martyna Szpakowska, Max Meyrath et al. · 2019 · Neuro-Oncology Advances
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
Tetsuya Mitsudomi, Kenichi Suda · 2013 · Lung Cancer Targets and Therapy
Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Kristoffer Staal Rohrberg, Juanita Suzanne Lopez, Mohammed M. Milhem, Christian U. Blank, Irene L. M. Reijers, Fiona C. Thistlethwaite, Ruth Plummer, Sarina Anne Piha-Paul, Pasi Antero Janne, Elaine Shum et al. · 2025 · Cancer Research Communications
RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression
Shaobo Huang, Jinling Zhang, Xiaoliang Wu, Baoxia Liang, Nengzhi Pang, Lili Yang, Zhenfeng Zhang · 2024 · Life Sciences
AXL inhibition prevents RPA2/CHK1-mediated homologous recombination to increase PARP inhibitor sensitivity in hepatocellular carcinoma
K. Li, Li-gong Deng, Lijun Xue, Chang Tan, Shukun Yao · 2024 · Heliyon
The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy
Mohsen Hashemi, Xaniar Mohammadi Khanaghah, Javid Sadri Nahand · 2025 · Functional & Integrative Genomics
Epithelial to Mesenchymal Transition
Annamarie C. Dalton, Philip H. Howe · 2021 · Elsevier eBooks
Generation of genetically engineered mice for lung cancer with mutant EGFR
Dasom Kim, Wonjun Ji, Dong Ha Kim, Yun Jung Choi, Kyungtaek Im, Chae Won Lee, Jeongin Cho, Joongkee Min, Dong‐Cheol Woo, Chang‐Min Choi et al. · 2022 · Biochemical and Biophysical Research Communications
Computational Tactics for Precision Cancer Network Biology
Heewon Park, Satoru Miyano · 2022 · International Journal of Molecular Sciences
A Review: The Potential Involvement of Growth Arrest-Specific 6 and Its Receptors in the Pathogenesis of Lung Damage and in Coronavirus Disease 2019
Daria Apostolo, Luciana L. Ferreira, Alice Di Tizio, Barbara Ruaro, Filippo Patrucco, Mattia Bellan · 2023 · Microorganisms
The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells
Daniela Frezzetti, Vincenza Caridi, Laura Marra, Rosa Camerlingo, Amelia D’Alessio, Francesco Paolo Russo, Serena Dotolo, Anna Maria Rachiglio, Riziero Esposito Abate, Marianna Gallo et al. · 2024 · International Journal of Molecular Sciences
Discovery and Characterization of Potent, Selective, and Orally Bioavailable 7-Azaindazole AXL Receptor Tyrosine Kinase Inhibitors
Corinne N. Foley, Shiwei Qu, Srinivas Reddy Paladugu, Manjunath Lamani, Rebecca L. Grange, Ehesan Ul Sharif, Joice Thomas, Pradeep Reddy Nareddy, Guiling Zhao, Yu Chen et al. · 2025 · Journal of Medicinal Chemistry
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells
Yue-qin Wang, Aijun Shen, Jingya Sun, Xin Wang, Hong‐Chun Liu, Minmin Zhang, Dan-Qi Chen, Bing Xiong, Jingkang Shen, Meiyu Geng et al. · 2016 · Acta Pharmacologica Sinica
Systems approaches to uncovering the contribution of environment-mediated drug resistance
Marc Creixell, Hyuna Kim, Farnaz Mohammadi, Shelly R. Peyton, Aaron S. Meyer · 2022 · Current Opinion in Solid State and Materials Science
Cooperative induction of receptor tyrosine kinase s contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway
Tine Norman Alver, Karen‐Marie Heintz, Eivind J. Hovig, Sigurd Leinæs Bøe · 2022 · Cancer Reports
Repurposing Axl Kinase Inhibitors for the Treatment of Respiratory Syncytial Virus Infection
Dan Zhang, Yuanhui Zhao, Xiaoxin You, Susu He, Erguang Li · 2023 · Antimicrobial Agents and Chemotherapy
Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion
Wayne A. Warner, Deborah J. L. Wong, Fernando Palma‐Diaz, Terry Y. Shibuya, Jamil Antonio Momand · 2015 · Case Reports in Oncological Medicine
Evaluating Synergistic Effects of miR-34a Mimics in Combination with Other Therapeutic Agents in Cultured Non-Small Cell Lung Cancer Cells
Jane Y. Zhao, Andreas G. Bader · 2016 · Methods in molecular biology
MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours
Michele Ghidini, Jens Claus Hahne, Melissa Frizziero, Gianluca Tomasello, Francesco Trevisani, Andrea Lampis, Rodolfo Passalacqua, Nicola Valeri · 2018 · Targeted Oncology
Uses of dimedone for the synthesis of thiazole derivatives as new anti-tumor, c-Met, tyrosine kinase, and Pim-1 inhibitions
Rafat M. Mohareb, Thomas Matthias Klapötke, Elena Reinhardt · 2018 · Medicinal Chemistry Research
Intact-cell MALDI-ToF mass spectrometry for the authentication of drug-adapted cancer cell lines
Povey, Jane F., Saintas, Emily, Aderemi, Adewale V., Rothweiler, Florian, Zehner, Richard, Dirks, Wilhelm G., Cinatl, Jindrich, Racher, Andrew J., Wass, Mark N., Smales, C. Mark et al. · 2019 · Cells
Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma
Sha Han, Yequan Wang, Chengyan Ge, Mingtao Gao, Xintong Wang, Feiyu Wang, Lei Sun, Sheng Li, Tingting Dong, Zhen Dang et al. · 2020 · Experimental and Therapeutic Medicine
Antiproliferative and Antiprostate Cancer Activities of Heterocyclic Compounds Derived from Cyclohexane-1,4-dione
Nadia Y. Megally Abdo, Rafat M. Mohareb · 2022 · Acta chimica slovenica
Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis
Sidra Younis, Qamar Javed, Miroslav Blumenberg · 2015 · BMC Cancer
Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Byoung Soo Kwon, Ji Hyun Park, Woo Sung Kim, Joon Seon Song, Chang‐Min Choi, Jin Kyung Rho, Jae Cheol Lee · 2017 · Tuberculosis & respiratory diseases
Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer
Xiuning Le, Sanjay Popat, John Victor Heymach, H. West, Lillian F. Zhang · 2026 · ESMO Open
CAR-T/NK/M-based combination therapies in cancer: A comprehensive review
Shivani Vaja, Swati Khandelwal, Chaitali Vora, Abdul Arif Khan, Syed Wajeed, M. Hassan Sk, Mirza S. Baig · 2026 · Current Problems in Cancer
Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis
Ji Young Kim, Gilyeong Nam, You Keun Shin, Nuria Vilaplana‐Lopera, Hei‐Cheul Jeung, Eui Jung Moon, Ik Jae Lee · 2023 · Cancers
Integrating Nanorobotics with Biophysics for Cancer Treatment
Rishabha Malviya, Deepika Yadav, Sonali Sundram, Seifedine Kadry, GURVINDER SINGH VIRK · 2024 · Institute of Physics eBooks
Multieffect Specific Nanovesicles for Homing Resistant Tumors and Overcoming Osimertinib‐Acquired Resistance in NSCLC
Yuanyao Dou, Yihui Liu, Rui Han, Jie Zheng, Liping Wang, Chen Hu, Daijuan Huang, Chao He, Yimin Zhang, Caiyu Lin et al. · 2025 · Advanced Healthcare Materials
Nanoparticle-Mediated Cosilencing of Drug Resistance and Compensatory Genes Enhances Lung Cancer Therapy
Dhananjay Suresh, S. Mukherjee, Ajit P. Zambre, Shreya Ghoshdastidar, Sairam Yadavilli, Karamkolly R. Rekha, Anandhi Upendran, Raghuraman Kannan · 2025 · ACS Nano
Tyrosine Kinase Inhibitors for EGFR Gene Mutation-Positive Non-SmallCell Lung Cancers: An Update for Recent Advances in Therapeutics
2015 · Journal of Pharmacovigilance
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma
Chiara Lazzari, Alberto Verlicchi, Αναστάσιος Γκουντάκος, Sara Pilotto, Mariacarmela Santarpía, Imane CHAIB-OUKADOUR, José Luis Ramírez, Santiago Viteri, Daniela Morales-Espinosa, Claudio Dazzi et al. · 2016 · Pulmonary Therapy
[Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].
Zitong Zhao, Yu Ni, Li Li, Tao Xin · 2020 · PubMed Central
AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors
Sharon M. Landers, Angela D. Bhalla, XiaoYan Ma, Kristelle Lusby, Davis R. Ingram, Ghadah A. Al Sannaa, Wei‐Lien Wang, Alexander J. Lazar, Keila E. Torres · 2020 · Journal of Cancer Science and Clinical Therapeutics
The Significance of Tumor Budding and Immunohistochemical Axl Expression in Gallbladder Adenocarcinomas
Özden Öz, Asuman Argon, Tulu Ayata Kebat, Çisem Namlı Akıncı, Özlem Özdemir · 2022 · Balkan Medical Journal
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs
Shuntaro Tsukamoto, Naoko Hata Sugi, Kyoko Nishibata, Youya Nakazawa, Daisuke Ito, Sayo Fukushima, Takayuki Nakagawa, Kenji Ichikawa, Yu Kato, Dai Kakiuchi et al. · 2022 · Molecular Cancer Therapeutics
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
Amanda R. Reyes, Rebecca R. Pharaon, Atish Ranjan Mohanty, Erminia Massarelli · 2023 · Cancers
Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor
Sevtap Çağlar Yavuz · 2023 · Karadeniz Fen Bilimleri Dergisi
State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA
Amin El Heliebi, Ellen Heitzer · 2019 · Elsevier eBooks
The up-regulation of Axl is associated with a poor prognosis and promotes proliferation in pancreatic ductal adenocarcinoma.
Weihua Yu, Xiaolong Ge, Xusheng Lai, Jiemin Lv, Yong Wang · 2019 · Europe PMC (PubMed Central)
Targeted Therapy for Non-Small Cell Lung Cancer
Jung Sun Kim, Eun Joo Kang · 2020 · Korean Journal of Medicine
Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma
Qiong Xu, Qiongfang Cha, Hui Qin, Bin Liu, Xueling Wu, Jiantao Shi · 2022 · Frontiers in Bioinformatics
Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status
DA-PING YU, Yujie Dong, HAI-QING ZHANG, Jinghui Wang, Yang Qu, LI-JUAN ZHOU, DAN SU, LI-LI ZHANG, Dan Zhao, Yiran Cai · 2014 · Biomedical Reports
A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
Hideyuki Niwa, Yoshiro Nakahara, Jiichiro Sasaki, Noriyuki Masuda · 2018 · BMJ Case Reports
Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform
Clara Mayo de las Casas, Mónica Garzón‐Ibáñez, Núria Jordana‐Ariza, Santiago Viteri, Irene Moya‐Horno, Niki Karachaliou, Zaira Yeste, Raquel Campos, Sergi Villatoro, Ariadna Balada‐Bel et al. · 2018 · Translational Cancer Research
3D-QSAR analysis of pyrimidine derivatives as AXL kinase inhibitors as anticancer agents
Siddharth J. Modi, Vithal M. Kulkarni · 2018 · Journal of Applied Pharmaceutical Science
Oncogenic Transcription Factors: Target Genes
Juliano D. Paccez, Luiz Fernando Zerbini · 2017 · Encyclopedia of Life Sciences
Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra‐Terminal Domain Inhibitors
Yosuke Miyashita, Ken Tajima, Kenta Izumi, Naohisa Matsumoto, Daisuke Hayakawa, Ikuko Takeda Nakamura, Isana Katayama, Adityo Wibowo, Hironari Matsuda, Wira Winardi et al. · 2025 · Cancer Science
Ti-Based Metallic Biomaterials for Antitumor Applications
Xiang Yan, Hui Liu, Zhe Zhang, Xiang Deng, Manfeng Lin, Zongyuan Cai, Dongying Tang, Hang Wang, Wen Liu, Dapeng Zhao · 2025 · Materials
AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer
Julien Ancel, Maxime Dewolf, Béatrice Nawrocki‐Raby, A. Durlach, Véronique Dalstein, Nathalie Lalun, Valérian Dormoy, Gaëtan Deslée, Christine Gilles, Myriam Polette · 2025 · Lung Cancer
Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
Xiaojuan Qiao, Ye Zhang, Jinghui Wang, Jingying Nong, Xi Li, Xinjie Yang, Jialin Lv, Hui Zhang, Na Qin, Quan Zhang et al. · 2015 · Thoracic Cancer
Mechanisms of microRNA Regulation of the Epithelial–Mesenchymal Transition (EMT) in Lung Cancer
Israel Martínez-Espinosa, José A. Serrato, Carlos Cabello-Gutiérrez, Ángeles Carlos‐Reyes, Blanca Ortíz-Quintero · 2024 · Life
Natural products combating EGFR-TKIs resistance in cancer
Xia Li, Gaohui Zhu, Qiyao Peng, Xiuyang Li, Xinrong Zou, Wanping Zhang, Lulu Zhao, Xiong Li, Pin Wu, Aimin Luo et al. · 2025 · European Journal of Medicinal Chemistry Reports
Label-Free Longitudinal Imaging of Single Cell Drug Response with a 3D-Printed Cell Culture Platform
Erin L. Dunnington, Kit Chiu, Brian S. Wong, Anthony Chales-Antonio, Victoria Pang, WU Yu-ling, Dan Fu · 2025 · Analytical Chemistry